Fig. 3: G4 ligand TMPyP4 reduces the tumor growth of the subcutaneous colorectal cancer model by increasing CD8+ T cells and DCs. | Cell Death & Disease

Fig. 3: G4 ligand TMPyP4 reduces the tumor growth of the subcutaneous colorectal cancer model by increasing CD8+ T cells and DCs.

From: Targeting G-quadruplex by TMPyP4 for inhibition of colorectal cancer through cell cycle arrest and boosting anti-tumor immunity

Fig. 3: G4 ligand TMPyP4 reduces the tumor growth of the subcutaneous colorectal cancer model by increasing CD8+ T cells and DCs.The alternative text for this image may have been generated using AI.

a Experimental treatment strategy for tumor growth inhibition in a syngeneic mouse tumor model. When tumors were palpable, mice were treated with vehicle or 30 mg/kg TMPyP4 three times a week (days 0, 3, 6). b, c The tumor size and tumor weight of BALB/C mice bearing CT26 colon cancer treated with vehicle or 30 mg/kg TMPyP4. n = 6 mice for both groups. d, e The tumor size and tumor weight of C57BL/6 mice bearing MC38 colon cancer treated with vehicle or 30 mg/kg TMPyP4. n = 6 mice for both groups. (f, g) The tumor size and tumor weight of nude mice bearing MC38 colon cancer treated with vehicle or 30 mg/kg TMPyP4. n = 6 mice for both groups. h, i Tumor growth inhibition comparison between C57BL/6 and nude mice after TMPyP4 treatment. j–p Graphs show the frequencies of CD45+ cells (j), CD3+ T cells (k), CD8+ T cells (l), DCs (m), CD4+ T cells (n), NK cells (o), and B cells (p) in CT26 tumors after TMPyP4 treatment or vehicle control treatment. q–w Graphs show the frequencies of CD45+ cells (q), CD3+ T cells (r), CD8+ T cells (s), DCs (t), CD4+ T cells (u), NK cells (v), and B cells (w) in MC38 tumors after TMPyP4 treatment or vehicle control treatment. ns: not significant, *p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001, by two-way ANOVA (b, d, f), or by untailed t-tests (c, e, g–w).

Back to article page